A Ligand That Targets CUG Trinucleotide Repeats

Area of Science:

• Chemical Biology
• Molecular Biology
• Drug Discovery

Background:

• Toxic RNA structures, such as expanded CUG trinucleotide repeats, are implicated in neurological disorders like myotonic dystrophy type 1 (DM1).
• These toxic RNA structures sequester essential proteins, like MBNL1, disrupting normal cellular function.
• Developing small molecules to target these specific RNA structures is a key area for therapeutic intervention.

Purpose of the Study:

• To rationally design, synthesize, and characterize a novel small molecule capable of recognizing and binding to toxic CUG trinucleotide repeats.
• To evaluate the specificity of the designed molecule against other RNA sequences.
• To assess the molecule's impact on gene expression modulation in vitro.

Main Methods:

• Rational molecular design and chemical synthesis of 2,9-diaminoalkyl-substituted 1,10-phenanthroline (DAP).
• Binding affinity and specificity assessment using melting temperature (Tm) analyses, surface plasmon resonance (SPR), and electrospray ionization time-of-flight (ESI-TOF) mass spectrometry.
• Functional evaluation of DAP's effect on RNA translation using a dual luciferase assay.

Main Results:

• DAP was successfully synthesized and demonstrated specific binding to r(CUG)9 repeats.
• Binding was not observed with r(CAG)9 or r(CGG)9 repeats, indicating high sequence specificity.
• The dual luciferase assay confirmed that DAP binds to r(CUG)n repeats and affects in vitro translation.

Conclusions:

• The developed DAP molecule is a potent and specific binder of CUG trinucleotide repeats.
• This discovery provides a promising molecular tool for further research into DM1 pathogenesis and potential therapeutic strategies.
• Targeting toxic RNA structures with specifically designed small molecules represents a viable approach for gene expression modulation.